Leading Neurological Rare Disease Biologics Market Companies: A Detailed Profile

Neurological Rare Disease Biologics Market Companies

• Alexion (AstraZeneca)
• Amgen
• Biogen
• Bluebird bio
• Catalent
• Eli Lilly
• Ionis Pharmaceuticals
• Novartis
• Pfizer
• Regenxbio
• Roche / Genentech
• Sanofi
• Sarepta Therapeutics
• Stoke Therapeutics
• UCB

Get Sample Report

1. Alexion (AstraZeneca)

• Company Name and Headquarters: Alexion Pharmaceuticals, Inc. (an AstraZeneca Company), headquartered in Boston, Massachusetts, USA.

• Product Offerings related to Neurological Rare Disease Biologics: Alexion is a leader in complement-mediated rare diseases. Their key product in the neurological rare disease space is Soliris (eculizumab), and its successor Ultomiris (ravulizumab), for conditions like:

  • Myasthenia Gravis (gMG): Specifically for generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody-positive.

  • Neuromyelitis Optica Spectrum Disorder (NMOSD): For adults who are anti-aquaporin-4 (AQP4) antibody-positive.

• Market Share and Estimated Revenue from Neurological Rare Disease Biologics Segment: Alexion holds a significant share in the gMG and NMOSD markets with Soliris and Ultomiris. While specific neurological rare disease revenue is not broken out separately from their overall rare disease portfolio, these drugs are major revenue drivers. Soliris generated over $3.8 billion globally in 2020 before its acquisition by AstraZeneca, with a substantial portion attributable to its neurological indications. Ultomiris, launched later, is rapidly growing and replacing Soliris in many indications due to its less frequent dosing.

• Recent Developments, Partnerships, or Innovations:

  • Continuous expansion of Ultomiris indications and global approvals.

  • Exploration of new complement inhibitors for other neurological conditions.

  • AstraZeneca’s acquisition of Alexion in 2021 significantly bolstered AstraZeneca’s rare disease portfolio.

• Competitive Positioning and Strategic Focus: Alexion’s strategy centers on developing and commercializing transformative therapies for ultra-rare diseases with high unmet needs, particularly those involving the complement system. Their competitive edge lies in deep expertise in complement biology and established market leadership in several rare conditions. They focus on global reach and patient access programs.

• Key Customers or Industries Served: Healthcare providers (neurologists, rare disease specialists), hospitals, infusion centers, and patients suffering from rare neurological autoimmune disorders.

2. Amgen

• Company Name and Headquarters: Amgen Inc., headquartered in Thousand Oaks, California, USA.

• Product Offerings related to Neurological Rare Disease Biologics: While Amgen has a broad biologics portfolio, its direct offerings in rare neurological diseases are more limited compared to some others on this list. Their focus has been more broadly on neuroscience, including migraine. For rare neurological diseases, their pipeline often involves collaborations.

  • Enspryng (satralizumab): Developed by Chugai (a member of the Roche Group) and co-marketed by Genentech (Roche) and Chugai. Amgen previously had a collaboration with Novartis on Aimovig (erenumab) for migraine prevention, which is a broader neurological indication, not specifically rare.

  • Amgen has a pipeline in neuroscience, with some potential for rare neurological conditions, but no currently marketed rare neurological biologics solely from Amgen in the same vein as Alexion or Biogen.

• Market Share and Estimated Revenue from Neurological Rare Disease Biologics Segment: Negligible direct market share in rare neurological biologics as a primary focus. Their revenue from neurology comes largely from more common conditions like migraine.

• Recent Developments, Partnerships, or Innovations:

  • Ongoing research in neuroinflammation and neurodegenerative diseases.

  • Focus on developing therapies for complex neurological disorders, often through partnerships.

• Competitive Positioning and Strategic Focus: Amgen’s strength is in biologics development and manufacturing. Their strategic focus in neuroscience includes exploring novel targets for neurodegenerative diseases and pain, but rare neurological diseases are not their primary rare disease focus, which tends to be more in oncology or bone health.

• Key Customers or Industries Served: Neurologists, pain specialists, hospitals, and patients.

3. Biogen

• Company Name and Headquarters: Biogen Inc., headquartered in Cambridge, Massachusetts, USA.

• Product Offerings related to Neurological Rare Disease Biologics: Biogen is a major player in neurological diseases, with a significant focus on rare conditions.

  • Spinraza (nusinersen): The first approved treatment for Spinal Muscular Atrophy (SMA). It’s an antisense oligonucleotide (ASO), a type of biologic, that increases production of the SMN protein.

  • Aduhelm (aducanumab): An amyloid-beta directed antibody for Alzheimer’s Disease. While AD is not “rare,” certain early-onset genetic forms could be considered within a broader rare disease context, but its broad approval and subsequent coverage limitations make its rare disease status complex.

  • Qalsody (Tofersen): An ASO approved for Amyotrophic Lateral Sclerosis (ALS) with a superoxide dismutase 1 (SOD1) mutation, a rare genetic form of ALS.

  • Vumerity (diroximel fumarate): While not a biologic and more for common MS, Biogen’s strong MS portfolio underscores their neuroscience expertise.

• Market Share and Estimated Revenue from Neurological Rare Disease Biologics Segment: Biogen holds a leading market share in SMA with Spinraza, which generated over $1.7 billion in 2022. Qalsody for SOD1-ALS is a newer, niche product but important for that specific rare population. Aduhelm’s revenue has been minimal due to coverage restrictions.

• Recent Developments, Partnerships, or Innovations:

  • Continued global rollout and lifecycle management for Spinraza.

  • Further research into biomarkers and combination therapies for SMA.

  • Significant investment in gene therapy for neurological disorders.

  • Research and development in Parkinson’s, ALS, and Alzheimer’s.

  • Partnership with Sage Therapeutics for depression therapies.

• Competitive Positioning and Strategic Focus: Biogen’s strategy is squarely focused on pioneering neuroscience. They aim to address high unmet needs in neurology, leveraging their deep scientific expertise in neurodegeneration and rare diseases. Their competitive advantage stems from their long-standing leadership in MS and successful entry into SMA.

• Key Customers or Industries Served: Neurologists, pediatric neurologists, rare disease specialists, hospitals, and patients with SMA, ALS (SOD1), and potentially early Alzheimer’s.

4. Bluebird bio

• Company Name and Headquarters: bluebird bio, Inc., headquartered in Somerville, Massachusetts, USA.

• Product Offerings related to Neurological Rare Disease Biologics: Bluebird bio specializes in gene therapies, which are a highly advanced form of biologics.

  • Skysona (elivaldogene autotemcel): A gene therapy for early, active Cerebral Adrenoleukodystrophy (CALD), a devastating neurological disease. It’s designed to slow the progression of neurological dysfunction.

• Market Share and Estimated Revenue from Neurological Rare Disease Biologics Segment: Skysona is a very recent approval (2022) and targets an ultra-rare population. Market share is nascent but critical for CALD. Revenue is currently low but expected to grow as access expands for this specialized, one-time treatment.

• Recent Developments, Partnerships, or Innovations:

  • Launch and commercialization of Skysona.

  • Focus on manufacturing and patient access for their gene therapies.

  • Divestment of their severe genetic disease and oncology businesses into separate entities (Bluebird bio focusing on severe genetic diseases, and 2seventy bio focusing on oncology).

• Competitive Positioning and Strategic Focus: Bluebird bio is a pioneer in gene therapy, focusing on transforming the lives of patients with severe genetic diseases. Their strategy involves developing highly specialized, one-time treatments for ultra-rare conditions. Their competitive edge is in their gene therapy platform and expertise in manufacturing and delivering these complex therapies.

• Key Customers or Industries Served: Specialized pediatric neurologists, metabolic disease specialists, transplant centers, and patients with CALD.

5. Catalent

• Company Name and Headquarters: Catalent, Inc., headquartered in Somerset, New Jersey, USA.

• Product Offerings related to Neurological Rare Disease Biologics: Catalent is a leading global contract development and manufacturing organization (CDMO). They do not have their own product offerings in neurological rare disease biologics. Instead, they provide critical services to pharmaceutical and biotech companies developing these products.

  • Services include: Biologics drug substance manufacturing (e.g., cell line development, upstream/downstream processing), sterile fill/finish, packaging, and advanced delivery technologies (e.g., viral vectors for gene therapy).

• Market Share and Estimated Revenue from Neurological Rare Disease Biologics Segment: Catalent does not have direct market share in selling neurological rare disease biologics. Their revenue comes from providing manufacturing and development services to companies that do. A significant portion of their biologics revenue would indirectly support the rare disease space, including neurological rare diseases, due to the high demand for CDMO services in this area.

• Recent Developments, Partnerships, or Innovations:

  • Significant investments in expanding gene therapy manufacturing capacity (e.g., through acquisitions of Paragon Bioservices).

  • Development of advanced cell line technologies for biologics production.

  • Partnerships with numerous biotech companies, many of which are developing rare disease therapies.

• Competitive Positioning and Strategic Focus: Catalent’s strategy is to be the leading partner for pharmaceutical innovation, providing end-to-end solutions for drug development and manufacturing. Their competitive advantage lies in their broad capabilities, global footprint, regulatory expertise, and ability to handle complex biologic modalities, including gene therapies.

• Key Customers or Industries Served: Pharmaceutical companies, biotechnology companies (including those focused on neurological rare diseases), and academic research institutions.

6. Eli Lilly

• Company Name and Headquarters: Eli Lilly and Company, headquartered in Indianapolis, Indiana, USA.

• Product Offerings related to Neurological Rare Disease Biologics: Lilly has a strong presence in neuroscience, particularly in Alzheimer’s disease, but their direct marketed products for rare neurological diseases are limited.

  • Donanemab: An investigational amyloid-beta targeting antibody for early Alzheimer’s Disease. While AD is common, early AD and some genetic forms could be viewed within a rare disease lens. Donanemab is a significant pipeline asset.

  • Their current marketed neurological products are generally for more common conditions (e.g., migraine with Emgality, psychiatric disorders).

• Market Share and Estimated Revenue from Neurological Rare Disease Biologics Segment: Minimal direct market share and revenue from marketed rare neurological biologics. Donanemab, if approved, would be a major revenue driver, but for a broad neurological indication.

• Recent Developments, Partnerships, or Innovations:

  • Extensive clinical trial program for Donanemab, with promising results for slowing cognitive decline in early AD.

  • Increased focus on neurodegenerative diseases through internal R&D and collaborations.

  • Pipeline includes therapies for Parkinson’s and other neurological conditions.

• Competitive Positioning and Strategic Focus: Lilly’s strategy in neuroscience focuses on addressing high unmet needs, particularly in neurodegeneration (Alzheimer’s) and pain. Their competitive edge comes from their extensive R&D capabilities and historical strength in drug development across various therapeutic areas.

• Key Customers or Industries Served: Neurologists, geriatricians, primary care physicians (for broader neurological conditions), and patients.

7. Ionis Pharmaceuticals

• Company Name and Headquarters: Ionis Pharmaceuticals, Inc., headquartered in Carlsbad, California, USA.

• Product Offerings related to Neurological Rare Disease Biologics: Ionis is a leader in antisense oligonucleotide (ASO) therapies, many of which target rare neurological diseases.

  • Spinraza (nusinersen): Developed in partnership with Biogen for Spinal Muscular Atrophy (SMA). Ionis discovered the drug and licensed it to Biogen.

  • Tegsedi (inotersen): For hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), a rare, progressive, and fatal disease that affects the nervous system.

  • Qalsody (Tofersen): Developed with Biogen for ALS with SOD1 mutation.

  • Wainua (eplontersen): In collaboration with AstraZeneca, this is a ligand-conjugated antisense (LCA) medicine for hATTR amyloidosis, expected to compete with Tegsedi.

• Market Share and Estimated Revenue from Neurological Rare Disease Biologics Segment: Ionis earns royalties from Spinraza, which generated over $1.7 billion for Biogen in 2022. Tegsedi contributes directly to Ionis’s revenue, competing in the hATTR space. Their innovation in ASO technology gives them a strong position.

• Recent Developments, Partnerships, or Innovations:

  • Continued advancement of their ASO pipeline, with multiple programs in clinical development for various neurological conditions (e.g., Huntington’s disease, familial amyloid polyneuropathy).

  • Strategic partnerships with major pharmaceutical companies (Biogen, AstraZeneca, Roche, GSK) to develop and commercialize their ASO candidates.

  • Focus on developing next-generation ASO technologies (e.g., LCAs) to improve potency and delivery.

• Competitive Positioning and Strategic Focus: Ionis’s strategy is to be the leader in RNA-targeted therapeutics, particularly ASOs. Their competitive advantage is their proprietary ASO platform, deep expertise in RNA biology, and a strong track record of discovering and developing therapies for challenging diseases, especially in neurology.

• Key Customers or Industries Served: Neurologists, geneticists, rare disease specialists, and patients with SMA, hATTR amyloidosis, and other rare neurological conditions.

8. Novartis

• Company Name and Headquarters: Novartis AG, headquartered in Basel, Switzerland.

• Product Offerings related to Neurological Rare Disease Biologics: Novartis has a strong presence in neuroscience and rare diseases.

  • Zolgensma (onasemnogene abeparvovec): A groundbreaking gene therapy for Spinal Muscular Atrophy (SMA), delivering a functional copy of the SMN1 gene.

  • Kesimpta (ofatumumab): An anti-CD20 antibody for relapsing multiple sclerosis (RMS). While MS is not rare, this biologic is a significant neurological offering.

  • Cosentyx (secukinumab): An IL-17A inhibitor, not primarily for rare neurological diseases, but illustrates their biologics capabilities.

• Market Share and Estimated Revenue from Neurological Rare Disease Biologics Segment: Novartis holds a significant market share in SMA with Zolgensma, which generated over $1.4 billion in 2022. It competes directly with Biogen’s Spinraza and Roche’s Evrysdi.

• Recent Developments, Partnerships, or Innovations:

  • Expansion of Zolgensma’s global reach and indications.

  • Ongoing clinical development in neuroscience, including gene therapies for other rare neurological conditions.

  • Focus on digital health and advanced therapy platforms.

• Competitive Positioning and Strategic Focus: Novartis aims to be a leading medicines company powered by advanced therapy platforms and data science. Their strategy in rare neurological diseases centers on transformative gene therapies and addressing high unmet needs. Zolgensma represents a significant competitive advantage in the SMA space.

• Key Customers or Industries Served: Pediatric neurologists, geneticists, rare disease specialists, hospitals, and patients with SMA.

9. Pfizer

• Company Name and Headquarters: Pfizer Inc., headquartered in New York, New York, USA.

• Product Offerings related to Neurological Rare Disease Biologics: Pfizer has a growing rare disease portfolio, with increasing focus on neurological conditions, particularly gene therapies.

  • Vyndaqel/Vyndamax (tafamidis): While a small molecule, it’s for transthyretin amyloid cardiomyopathy (ATTR-CM) and hereditary transthyretin-mediated amyloidosis with polyneuropathy (hATTR-PN), a rare neurological condition.

  • Gene therapy pipeline: Pfizer has a robust gene therapy pipeline for various rare diseases, including neurological ones such as Duchenne Muscular Dystrophy (DMD) and Friedreich’s Ataxia (FA). They have investigational gene therapies for these conditions.

• Market Share and Estimated Revenue from Neurological Rare Disease Biologics Segment: Vyndaqel/Vyndamax is a blockbuster drug, with substantial revenue for Pfizer (over $2.4 billion in 2022), much of which comes from its ATTR-PN indication. Their gene therapy pipeline is expected to be a future revenue driver in rare neurological diseases.

• Recent Developments, Partnerships, or Innovations:

  • Acquisition of companies with gene therapy expertise (e.g., Bamboo Therapeutics).

  • Advanced clinical trials for their DMD and FA gene therapy candidates.

  • Significant investment in rare disease research and development.

• Competitive Positioning and Strategic Focus: Pfizer’s strategy involves leveraging its global scale and R&D capabilities to address rare diseases, with a strong focus on gene therapy and other advanced modalities. Their competitive edge comes from their broad portfolio, global reach, and commitment to developing therapies for high unmet needs.

• Key Customers or Industries Served: Neurologists, cardiologists, geneticists, rare disease specialists, and patients with ATTR amyloidosis, DMD, and FA.

10. Regenxbio

• Company Name and Headquarters: Regenxbio Inc., headquartered in Rockville, Maryland, USA.

• Product Offerings related to Neurological Rare Disease Biologics: Regenxbio is a leading clinical-stage biotechnology company focused on gene therapy. They develop AAV (adeno-associated virus) gene therapies.

  • RGX-121: An investigational gene therapy for Mucopolysaccharidosis Type II (MPS II), or Hunter syndrome, with neurological manifestations.

  • RGX-111: An investigational gene therapy for Mucopolysaccharidosis Type I (MPS I), or Hurler syndrome, with neurological manifestations.

  • RGX-314: While primarily for wet AMD and diabetic retinopathy, it showcases their AAV platform technology.

• Market Share and Estimated Revenue from Neurological Rare Disease Biologics Segment: As a clinical-stage company, Regenxbio currently has no marketed products for neurological rare diseases and thus no direct market share or revenue from this segment. Their revenue comes from partnerships and milestone payments.

• Recent Developments, Partnerships, or Innovations:

  • Advancement of their MPS II and MPS I gene therapy programs through clinical trials.

  • Development of their proprietary NAV® Technology Platform for AAV vectors.

  • Strategic collaborations to apply their gene therapy platform across various therapeutic areas.

• Competitive Positioning and Strategic Focus: Regenxbio’s strategy is to be a leader in gene therapy, focusing on developing and commercializing transformative AAV-based treatments for severe diseases, including those with neurological components. Their competitive advantage is their proprietary NAV Technology Platform and expertise in AAV vector development and manufacturing.

• Key Customers or Industries Served: Primarily research institutions and pharmaceutical partners; in the future, geneticists, pediatric neurologists, and patients with MPS I and II.

11. Roche / Genentech

• Company Name and Headquarters: F. Hoffmann-La Roche AG (Roche), headquartered in Basel, Switzerland. Genentech (a member of the Roche Group) is headquartered in South San Francisco, California, USA.

• Product Offerings related to Neurological Rare Disease Biologics: Roche/Genentech is a significant force in neuroscience, with several key biologics for rare neurological conditions.

  • Evrysdi (risdiplam): An oral small molecule for Spinal Muscular Atrophy (SMA), which modifies SMN2 splicing. While a small molecule, it directly competes with biologic SMA treatments.

  • Ocrevus (ocrelizumab): An anti-CD20 antibody for multiple sclerosis (MS), including primary progressive MS (PPMS) and relapsing-remitting MS (RRMS). While MS is not rare, PPMS is a severe, less common form.

  • Enspryng (satralizumab): An anti-IL-6 receptor antibody for Neuromyelitis Optica Spectrum Disorder (NMOSD), a rare autoimmune neurological disease.

  • Pipeline: Robust pipeline including gene therapies and antibodies for Huntington’s disease, Alzheimer’s, Parkinson’s, and other neurodegenerative conditions.

• Market Share and Estimated Revenue from Neurological Rare Disease Biologics Segment: Roche holds substantial market share in SMA with Evrysdi, which generated over $1.2 billion in 2022. Ocrevus is a blockbuster MS drug (over $6 billion in 2022), with a portion attributable to PPMS. Enspryng is a key competitor in the NMOSD market.

• Recent Developments, Partnerships, or Innovations:

  • Continued global expansion and real-world evidence generation for Evrysdi, Ocrevus, and Enspryng.

  • Heavy investment in neuroscience R&D, particularly in Alzheimer’s disease (e.g., gantenerumab, though it failed in trials, shows their commitment).

  • Exploration of novel modalities like gene therapy and ASOs for neurodegenerative diseases.

• Competitive Positioning and Strategic Focus: Roche/Genentech’s strategy is to be a leader in oncology, immunology, and neuroscience, focusing on personalized healthcare. Their competitive edge in rare neurological diseases comes from their deep R&D capabilities, strong clinical development, and global commercial infrastructure. They aim to deliver transformative medicines for high unmet needs.

• Key Customers or Industries Served: Neurologists, rare disease specialists, hospitals, and patients with SMA, MS, and NMOSD.

12. Sanofi

• Company Name and Headquarters: Sanofi S.A., headquartered in Paris, France.

• Product Offerings related to Neurological Rare Disease Biologics: Sanofi has a long history in rare diseases, particularly through its Genzyme acquisition, with a strong focus on lysosomal storage disorders (LSDs), many of which have neurological manifestations.

  • Cerezyme (imiglucerase): For Gaucher disease, a lysosomal storage disorder that can have neurological complications.

  • Fabrazyme (agalsidase beta): For Fabry disease, another LSD with neurological symptoms (neuropathic pain).

  • Aldurazyme (laronidase): For Mucopolysaccharidosis I (MPS I), which affects the brain and spinal cord.

  • Lemtrada (alemtuzumab): For relapsing forms of Multiple Sclerosis (MS). While MS is not rare, Lemtrada is a high-efficacy, specialized biologic.

  • Pipeline: Strong pipeline in rare diseases, including gene therapies and novel biologics for neurological conditions.

• Market Share and Estimated Revenue from Neurological Rare Disease Biologics Segment: Sanofi holds significant market share in the treatment of various LSDs, with Cerezyme and Fabrazyme being long-standing revenue drivers. While specific neurological revenue is not isolated, a substantial portion of their rare disease revenue (over €3.8 billion in 2022 from Rare Diseases GBU) comes from products treating diseases with neurological involvement.

• Recent Developments, Partnerships, or Innovations:

  • Acquisition of Translate Bio to bolster mRNA therapeutics capabilities, with potential for neurological applications.

  • Continued investment in gene therapy platforms for rare diseases.

  • Focus on expanding the indications and global access for their existing rare disease portfolio.

• Competitive Positioning and Strategic Focus: Sanofi’s strategy in rare diseases is to build on its legacy leadership, leveraging its expertise in lysosomal storage disorders and expanding into gene therapies and other advanced modalities. Their competitive edge is their established rare disease infrastructure, patient support programs, and global presence.

• Key Customers or Industries Served: Geneticists, neurologists, metabolic disease specialists, hospitals, and patients with Gaucher, Fabry, MPS I, and MS.

13. Sarepta Therapeutics

• Company Name and Headquarters: Sarepta Therapeutics, Inc., headquartered in Cambridge, Massachusetts, USA.

• Product Offerings related to Neurological Rare Disease Biologics: Sarepta is a leader in therapies for Duchenne Muscular Dystrophy (DMD), a rare, progressive, and fatal genetic neurological muscle-wasting disease. Their products are primarily RNA-targeted therapies (ASOs) and gene therapies.

  • Exondys 51 (eteplirsen): An antisense oligonucleotide for DMD patients amenable to exon 51 skipping.

  • Vyondys 53 (golodirsen): An antisense oligonucleotide for DMD patients amenable to exon 53 skipping.

  • Amondys 45 (casimersen): An antisense oligonucleotide for DMD patients amenable to exon 45 skipping.

  • Elevidys (delandistrogene moxeparvovec): A groundbreaking gene therapy for ambulatory DMD patients aged 4-5 years with a confirmed mutation in the DMD gene.

• Market Share and Estimated Revenue from Neurological Rare Disease Biologics Segment: Sarepta holds a dominant market share in exon-skipping therapies for DMD, and with Elevidys, they are pioneering gene therapy for DMD. Their net product revenues were over $933 million in 2022, primarily from their DMD portfolio. Elevidys is expected to be a major revenue driver, significantly expanding their market.

• Recent Developments, Partnerships, or Innovations:

  • Accelerated approval and launch of Elevidys, marking a significant milestone in DMD gene therapy.

  • Continued research into novel RNA-targeted and gene therapies for DMD and other rare neuromuscular diseases.

  • Expanding global regulatory submissions for their therapies.

• Competitive Positioning and Strategic Focus: Sarepta’s strategy is to be the leader in precision genetic medicine for rare neuromuscular diseases, especially DMD. Their competitive advantage is their deep expertise in RNA biology and gene therapy for neuromuscular disorders, their strong patient advocacy, and their first-mover advantage in DMD treatments.

• Key Customers or Industries Served: Pediatric neurologists, neuromuscular specialists, geneticists, hospitals, and patients with DMD.

14. Stoke Therapeutics

• Company Name and Headquarters: Stoke Therapeutics, Inc., headquartered in Bedford, Massachusetts, USA.

• Product Offerings related to Neurological Rare Disease Biologics: Stoke Therapeutics is a clinical-stage biotechnology company developing novel RNA-targeted medicines to increase protein expression.

  • STK-001: An investigational antisense oligonucleotide (ASO) for Dravet Syndrome, a severe and rare genetic epilepsy. STK-001 is designed to increase the expression of the SCN1A gene.

• Market Share and Estimated Revenue from Neurological Rare Disease Biologics Segment: As a clinical-stage company, Stoke Therapeutics has no marketed products for neurological rare diseases and therefore no direct market share or revenue from this segment. Their revenue comes from R&D and potential future milestone payments.

• Recent Developments, Partnerships, or Innovations:

  • Advancement of STK-001 through clinical trials for Dravet Syndrome.

  • Development of their TANGO (Targeted Augmentation of Nuclear Gene Output) platform to address diseases caused by haploinsufficiency (where one copy of a gene is mutated, leading to insufficient protein).

  • Pipeline expansion into other rare genetic neurological conditions.

• Competitive Positioning and Strategic Focus: Stoke’s strategy is to pioneer a new class of RNA medicines that can increase protein production. Their competitive advantage is their TANGO platform, which offers a unique approach to treating genetic diseases caused by haploinsufficiency, particularly in the neurological space.

• Key Customers or Industries Served: Primarily research institutions; in the future, pediatric neurologists, epileptologists, geneticists, and patients with Dravet Syndrome.

15. UCB

• Company Name and Headquarters: UCB S.A., headquartered in Brussels, Belgium.

• Product Offerings related to Neurological Rare Disease Biologics: UCB has a significant focus on neurology and immunology, with a growing presence in rare neurological diseases.

  • Zilbrysq (zilucoplan): A C5 inhibitor for generalized Myasthenia Gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive. It is a new entry into the gMG market, competing with Soliris/Ultomiris.

  • Rystiggo (rozanolixizumab): An anti-FcRn monoclonal antibody also for generalized Myasthenia Gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive or anti-muscle-specific tyrosine kinase (MuSK) antibody-positive.

  • Faycomp (perampanel): While a small molecule, it’s for epilepsy.

  • UCB also has a pipeline focusing on other neurological conditions, including rare ones.

• Market Share and Estimated Revenue from Neurological Rare Disease Biologics Segment: UCB is a newer entrant into the gMG biologics market with Zilbrysq and Rystiggo (both approved in 2023). Their market share is currently building but expected to grow rapidly due to the differentiated mechanisms of action and patient convenience (subcutaneous administration). Revenue from these new launches will be a significant new segment for UCB.

• Recent Developments, Partnerships, or Innovations:

  • Successful clinical trials and regulatory approvals for Zilbrysq and Rystiggo, marking a major expansion of their rare disease neurology portfolio.

  • Ongoing research and development into novel targets for neuroinflammation and neurodegeneration.

  • Acquisition of Zogenix to strengthen its epilepsy franchise.

• Competitive Positioning and Strategic Focus: UCB’s strategy is to focus on discovering and developing innovative medicines for people living with severe diseases in immunology and neurology. Their competitive edge in rare neurological diseases is their commitment to addressing unmet needs in gMG and leveraging their expertise in developing targeted biologics. They aim to offer differentiated options to patients.

• Key Customers or Industries Served: Neurologists, rare disease specialists, hospitals, and patients with generalized Myasthenia Gravis.

Contact Us